Shots: Mylan signed an agreement to acquire the related IP and commercialization rights of Aspen’s thrombosis business in the EU for $758.59M which include ~$311.08M as up front and ~$447.46 […]readmore
Tags : Aspen
Shots: Aspen to receive $330.68M up front along with up to $110.22M deferred consideration upon fulfillment of certain conditions, making a total deal value ~$440.9M. The transaction is anticipated to […]readmore